Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    

ALLERGAN, INC.
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Allergan, Inc. : CORRECT : Allergan 4Q Net Rose 6.3%, Margins Improve; R&D Costs Higher

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/02/2012 | 05:30pm CEST

("Allergan 4Q Net Falls 6.3% On Higher R&D Costs; Margins Improve," at 9:41 a.m. EST, misstated the earnings change direction in the headline and first and fourth paragraphs. A corrected version follows:)

Allergan Inc.'s (>> Allergan, Inc.) fourth-quarter earnings rose 6.3% and margins improved, though the Botox maker saw a sharp rise in research-and-development costs and booked one-time items.

The company also forecast current-quarter earnings of 84 cents to 86 cents a share on revenue of $1.34 billion and $1.39 billion, while analysts surveyed by Thomson Reuters expect 91 cents on $1.38 billion. Allergan also expects full-year earnings of $4.13 to $4.19 a share on revenue between $5.65 billion and $5.85 billion. Analysts were expecting $4.21 a share on $5.89 billion for the year.

Allergan has seen its revenue grow for more than two years, aided by surging sales of the wrinkle-fighting drug Botox. The injectable neurotoxin is approved for both cosmetic use and for treating various medial issues. Allergan has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (>> MAP Pharmaceuticals Inc.) to jointly promote Map's experimental migraine treatment Levadex. Allergan's Botox was also approved in August as a treatment for urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan reported a profit of $279.8 million, or 90 cents a share, up from $263.1 million, or 85 cents, a year earlier. Excluding items such as amortization, realignment and litigation costs, earnings rose to $1 a share from 88 cents. Revenue jumped 7.1% to $1.4 billion.

Its October projection was earnings of 97 cents to 99 cents a share on sales of $1.33 billion to $1.41 billion.

Operating margin rose to 29.2% from 28.1%.

Research and development costs jumped 13% to $226.4 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue--rose 8.9%. Revenue from the medical-device segment, which includes breast implants and the Lap-Band System for obesity, decreased 1%.

Shares were trading 1.9% lower at $85.63 premarket. The stock has risen 4.7% over the past three months through Wednesday's close.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected] 

Stocks mentioned in the article : Allergan, Inc., MAP Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
2017Mylan defends chairman to ISS ahead of June 22 investor vote
RE
2017ALLERGAN : to Present New Data on Chronic Migraine at the American Headache Soci..
PU
2017U.S. state, local government lawsuits over opioids face uphill battle
RE
2017ALLERGAN : to Present Data from its Anti-Infectives Portfolio at ASM Microbe 201..
PU
2017ALLERGAN : Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch R..
PU
2017ALLERGAN : Eyepowerment™ Campaign Releases Survey Revealing the Importance..
PU
2017Several top fund managers trim Allergan stakes in first quarter
RE
2017CARL ICAHN : Icahn takes new 19.8 million share stake in Conduent in first quart..
RE
2017High-profile Snap stakeholders revealed in filings
RE
2017High-profile Snap stakeholders revealed in filings
RE
More news
News from SeekingAlpha
2015MANNKIND : A Head Pain Gain Or A Pocket-Book Drain? 
2015Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update 
2015Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update 
2015Time Warner Is A Buy - Cramer's Lightning Round (5/21/15) 
2015Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update 
Managers
NameTitle
Ambrose Robert Douglas Bailey Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
Raymond H. Diradoorian Executive VP-Global Technical Operations
Joann Bradley Investor Relations Contact
Cathy Taylor Media Relations Contact
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.0
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189